skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Hello,

My portfolio is currently underweight in healthcare and I am looking to add either ZUH or XHC. My goal is long-term growth rather than income, so I think either of these would be a better fit than HHL or LIFE. Looking through past questions, it seems that your preference has been for XHC due to its greater diversification, global exposure, and better valuations of its underlying holdings.

I was wondering if you would still prefer XHC over ZUH? Or has the current pullback done anything to alter your view on these ETFs?

Thank you for thoughts and for the excellent service.
Read Answer Asked by Andrew on January 28, 2022
Q: Hello!
What is the likelihood of WELL needing cash giving the share price drop, potential acquisitions, and value returning (or not) to the sector. Are we taking on unnecessary risk holding it at these levels under water? I really like the execution team and their strategy, but sometimes there are things the business cannot control. Would love to see them continuing expanding paying penny on the dollar, I don't see any insider selling so far at glance, encouraging.
Thank you!
Read Answer Asked by Etienne on January 20, 2022
Q: Telus, Maple, Well and others are Canadian stocks in the medical game in Canada and the USA. Are there other Canadian players in the same league? Can you please compare them from a financial performance, competitive and management perspective. Well has dropped by 50% since Sept/2021, very gradually. I'm wondering if there is a reason for the gradual decline. Is there a better stock in the same sector? Canadian or US. Also, is there still momentum pushing down WELL. Do you think it will be beaten by the competition in the next 2-3 years? Is it a sell from this perspective?
Read Answer Asked by TOM on January 18, 2022